Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely ...

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with ...

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

A new study shows low rates of pre-exposure prophylaxis (PrEP) prescribing to sexual and gender minority individuals living ...

Seventy percent of Asian American and Pacific Islander women diagnosed with lung cancer were non- or never-smokers, ...

Ayodeji Adegunsoye, MD, PhD, MSc, discusses how emerging genetic insights like telomere-related mutations may reshape disease ...

The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.

A panelist emphasizes that while trispecific antibodies offer near-perfect response rates and convenient monthly dosing that ...

In this new study, investigators sought to measure and attribute out-of-pocket costs to cancer stage and by diagnosis.

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 ...